T. Rowe Price Associates, Inc. 13D and 13G filings for Vera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 10:07 am Sale | 2026-03-31 | 13G | VERA THERAPEUTICS INC VERA | T. Rowe Price Associates, Inc. | 4,573,684 6.400% | -888,304 (-16.26%) | Filing |
| 2026-02-17 10:26 am Purchase | 2025-12-31 | 13G | VERA THERAPEUTICS INC VERA | T. Rowe Price Associates, Inc. | 5,461,988 7.700% | 1,795,390 (+48.97%) | Filing |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | VERA THERAPEUTICS INC VERA | T. Rowe Price Associates, Inc. | 3,666,598 5.700% | -272,511 (-6.92%) | Filing |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | VERA THERAPEUTICS INC VERA | T. Rowe Price Associates, Inc. | 3,939,109 7.200% | 3,939,109 (New Position) | Filing |